A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by ... - UroToday
NURE-Combo trial evaluated nivolumab + nab-paclitaxel as neoadjuvant therapy for MIBC, followed by RC and adjuvant nivolumab. 31 patients enrolled; 32.3% achieved ypT0N0 response, 70.9% ypT≤1N0-x. 12-month EFS was 89.8%. First results suggest potential for immune-chemotherapy in MIBC.
Highlighted Terms
Related News
The NURE-Combo trial showed neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab was safe and active in muscle-invasive bladder cancer patients, achieving a 32.3% ypT0N0 response. The combination's safety profile was manageable, with no grade 4 or higher adverse events reported.
NURE-Combo trial evaluated nivolumab + nab-paclitaxel as neoadjuvant therapy for MIBC, followed by RC and adjuvant nivolumab. 31 patients enrolled; 32.3% achieved ypT0N0 response, 70.9% ypT≤1N0-x. 12-month EFS was 89.8%. First results suggest potential for immune-chemotherapy in MIBC.